iCAD (NASDAQ:ICAD) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of iCAD (NASDAQ:ICAD) from a sell rating to a hold rating in a research report released on Thursday morning.

iCAD Stock Down 4.6 %

Shares of NASDAQ:ICAD opened at $2.70 on Thursday. iCAD has a fifty-two week low of $1.18 and a fifty-two week high of $3.78. The firm has a 50-day simple moving average of $2.48 and a 200 day simple moving average of $1.95. The company has a market cap of $71.66 million, a PE ratio of -20.77 and a beta of 1.47.

Institutional Investors Weigh In On iCAD

A number of institutional investors have recently modified their holdings of ICAD. waypoint wealth counsel grew its position in shares of iCAD by 44.0% during the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock valued at $26,000 after buying an additional 4,400 shares during the last quarter. Summit Trail Advisors LLC acquired a new position in iCAD during the 4th quarter valued at about $214,000. Thompson Davis & CO. Inc. acquired a new position in iCAD during the 4th quarter valued at about $31,000. First Eagle Investment Management LLC boosted its stake in iCAD by 6.1% during the 4th quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company’s stock valued at $1,311,000 after purchasing an additional 41,000 shares during the period. Finally, PKS Advisory Services LLC acquired a new position in iCAD during the 4th quarter valued at about $53,000. Institutional investors own 24.61% of the company’s stock.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.